HRP20190674T1 - Bifunkcionalni polipeptidi - Google Patents
Bifunkcionalni polipeptidi Download PDFInfo
- Publication number
- HRP20190674T1 HRP20190674T1 HRP20190674TT HRP20190674T HRP20190674T1 HR P20190674 T1 HRP20190674 T1 HR P20190674T1 HR P20190674T T HRP20190674T T HR P20190674TT HR P20190674 T HRP20190674 T HR P20190674T HR P20190674 T1 HRP20190674 T1 HR P20190674T1
- Authority
- HR
- Croatia
- Prior art keywords
- immune effector
- bifunctional molecule
- molecule according
- effector polypeptide
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 16
- 230000001588 bifunctional effect Effects 0.000 title claims 13
- 239000012642 immune effector Substances 0.000 claims 11
- 229940121354 immunomodulator Drugs 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Bifunkcionalna molekula koja sadrži polipeptid vezujućeg partnera specifičnog za dani pMHC epitop, i imunološki efektorski polipeptid, gdje je N-kraj pMHC vezujućeg partnera vezan na C-kraj imunološkog efektorskog polipeptida, naznačena time što je polipeptid vezujući partner antitijelo.
2. Bifunkcionalna molekula prema zahtjevu 1, naznačena time što je imunološki efektorski polipeptid antitijelo koje se specifično veže na antigen predstavljen T-stanicom.
3. Bifunkcionalna molekula prema zahtjevu 2, naznačena time što je antitijelo scFv antitijelo.
4. Bifunkcionalna molekula prema zahtjevu 2 ili zahtjevu 3, naznačena time što je imunološki efektorski polipeptid anti-CD3 antitijelo.
5. Bifunkcionalna molekula prema zahtjevu 4, naznačena time što je imunološki efektorski polipeptid OKT3.
6. Bifunkcionalna molekula prema zahtjevu 4, naznačena time što je imunološki efektorski polipeptid UCHT-1.
7. Bifunkcionalna molekula prema zahtjevu 4, naznačena time što je imunološki efektorski polipeptid BMA031.
8. Bifunkcionalna molekula prema zahtjevu 4, naznačena time što je imunološki efektorski polipeptid 12F6.
9. Bifunkcionalna molekula prema zahtjevu 1, naznačena time što je imunološki efektorski polipeptid citokin koji modulira imunosupresivnu ili imunostimulatornu aktivnost limfocita.
10. Bifunkcionalna molekula prema bilo kojem od prethodnih zahtjeva, naznačena time što su polipeptid vezujući partner i imunološki efektorski polipeptid direktno povezani.
11. Bifunkcionalna molekula prema bilo kojem od zahtjeva 1 do 9, naznačena time što su polipeptid vezujući partner i imunološki efektorski polipeptid indirektno povezani kroz veznu sekvencu.
12. Bifunkcionalna molekula prema zahtjevu 11, naznačena time što je vezna sekvenca manja od 12, manja od 10 ili od 5-10 aminokiselina po dužini.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0908613.3A GB0908613D0 (en) | 2009-05-20 | 2009-05-20 | T Cell Reseptors |
EP16176246.3A EP3112376B1 (en) | 2009-05-20 | 2010-05-19 | Bifunctional polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190674T1 true HRP20190674T1 (hr) | 2019-08-09 |
Family
ID=40834242
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170086TT HRP20170086T1 (hr) | 2009-05-20 | 2017-01-19 | Bifunkcionalni polipeptidi |
HRP20180757TT HRP20180757T1 (hr) | 2009-05-20 | 2018-05-15 | Bifunkcionalni polipeptidi |
HRP20190674TT HRP20190674T1 (hr) | 2009-05-20 | 2019-04-09 | Bifunkcionalni polipeptidi |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170086TT HRP20170086T1 (hr) | 2009-05-20 | 2017-01-19 | Bifunkcionalni polipeptidi |
HRP20180757TT HRP20180757T1 (hr) | 2009-05-20 | 2018-05-15 | Bifunkcionalni polipeptidi |
Country Status (21)
Country | Link |
---|---|
US (6) | US10130721B2 (hr) |
EP (3) | EP2432802B1 (hr) |
JP (4) | JP5667171B2 (hr) |
CN (1) | CN102439034B (hr) |
AU (1) | AU2010250951B2 (hr) |
BR (1) | BRPI1013029A2 (hr) |
CA (2) | CA2968393C (hr) |
CY (3) | CY1118405T1 (hr) |
DK (3) | DK3112376T3 (hr) |
EA (1) | EA020841B1 (hr) |
ES (3) | ES2721058T3 (hr) |
GB (1) | GB0908613D0 (hr) |
HR (3) | HRP20170086T1 (hr) |
HU (3) | HUE043245T2 (hr) |
LT (3) | LT3112377T (hr) |
MX (1) | MX340168B (hr) |
PL (3) | PL2432802T3 (hr) |
PT (3) | PT3112377T (hr) |
SI (3) | SI3112377T1 (hr) |
TR (2) | TR201905437T4 (hr) |
WO (1) | WO2010133828A1 (hr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
LT2665486T (lt) | 2011-01-18 | 2020-04-10 | Bioniz, Llc | Kompozicijos, skirtos gama-c-citokino aktyvumui moduliuoti |
ES2689512T3 (es) | 2011-09-15 | 2018-11-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptores de células T que reconocen MAGE restringido por HLA-A1 o a HLA-Cw7 |
EP2760892A1 (en) * | 2011-09-29 | 2014-08-06 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
CN104870011A (zh) | 2011-11-03 | 2015-08-26 | 托莱拉医疗股份有限公司 | 选择性抑制t细胞应答的抗体和方法 |
EP2802356A1 (en) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
ES2740930T3 (es) | 2014-03-14 | 2020-02-07 | Immunocore Ltd | Bibliotecas de TCR |
CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
US11851469B2 (en) | 2014-11-07 | 2023-12-26 | Xlifesc, Ltd. | Soluble heterodimeric T cell receptor, and preparation method and use thereof |
GB201516270D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516269D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516265D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516277D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR libraries |
GB201516275D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516274D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
KR20240047483A (ko) | 2015-10-09 | 2024-04-12 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 조정 |
GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520558D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520546D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520545D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
GB201520548D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520557D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520575D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201607535D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520597D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520562D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520567D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520603D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520536D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520570D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520543D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520542D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
PL3430037T3 (pl) * | 2016-03-16 | 2022-12-19 | Immatics Biotechnologies Gmbh | Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej |
GB201604953D0 (en) | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
MX2018012318A (es) | 2016-04-08 | 2019-07-04 | Immunocore Ltd | Receptores de celulas t. |
WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
JP2019517499A (ja) | 2016-06-02 | 2019-06-24 | イムノコア リミテッド | gp100特異的TCR−抗CD3 scFv融合タンパク質の投薬レジメン |
WO2018081784A1 (en) * | 2016-10-31 | 2018-05-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells for expanding immune cells for immunotherapy |
US20210115099A1 (en) | 2016-11-07 | 2021-04-22 | Immunocore Limited | Peptides |
CN108203459A (zh) * | 2016-12-19 | 2018-06-26 | 广东香雪精准医疗技术有限公司 | 源自于prame的肿瘤抗原短肽 |
GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
CA3100253A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
WO2020147708A1 (en) * | 2019-01-14 | 2020-07-23 | Nanjing Legend Biotech Co., Ltd. | Chimeric receptor polypeptides and uses thereof |
CA3126611A1 (en) | 2019-01-17 | 2020-07-23 | Immunocore Limited | Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins |
GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
US20220152109A1 (en) | 2019-03-18 | 2022-05-19 | Ludwig Institute For Cancer Research Ltd | A2/ny-eso-1 specific t cell receptors and uses thereof |
GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
WO2023288203A2 (en) | 2021-07-12 | 2023-01-19 | Ludwig Institute For Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药(杭州)有限公司 | 一种接近天然分子的多肽融合分子 |
EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
WO2023156663A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Limited | Hiv-specific binding molecules and tcr |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024067821A1 (zh) * | 2022-09-30 | 2024-04-04 | 瑅安生物医药(杭州)有限公司 | 一种修饰细胞及其用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ID28040A (id) * | 1998-05-19 | 2001-05-03 | Avidex Ltd | Reseptor sel t yang dapat larut |
JP4467188B2 (ja) * | 1998-10-21 | 2010-05-26 | アルター・バイオサイエンス・コーポレーション | 多重特異的結合分子とその使用 |
EP1287363A2 (en) * | 2000-05-25 | 2003-03-05 | Sunol Molecular Corporation | Modulation of t-cell receptor interactions |
AU2001275246B2 (en) * | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
PL208712B1 (pl) * | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
EP1765860B1 (en) | 2004-05-19 | 2008-12-10 | MediGene Ltd. | High affinity ny-eso t cell receptor |
US20090042285A1 (en) | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
CA2567814C (en) * | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
AU2005251563B2 (en) * | 2004-06-09 | 2011-08-04 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
CA2582963A1 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
AU2006327175A1 (en) * | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
EP2527370A1 (en) * | 2005-12-21 | 2012-11-28 | Amgen Research (Munich) GmbH | Compounds having resistance to soluble CEA |
GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
GB0816096D0 (en) | 2008-09-04 | 2008-10-15 | Medigene Ltd | Diabetes t cell receptors |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
-
2009
- 2009-05-20 GB GBGB0908613.3A patent/GB0908613D0/en not_active Ceased
-
2010
- 2010-05-19 PT PT161762497T patent/PT3112377T/pt unknown
- 2010-05-19 DK DK16176246.3T patent/DK3112376T3/en active
- 2010-05-19 US US13/319,597 patent/US10130721B2/en active Active
- 2010-05-19 PT PT107208035T patent/PT2432802T/pt unknown
- 2010-05-19 EA EA201101660A patent/EA020841B1/ru not_active IP Right Cessation
- 2010-05-19 LT LTEP16176249.7T patent/LT3112377T/lt unknown
- 2010-05-19 TR TR2019/05437T patent/TR201905437T4/tr unknown
- 2010-05-19 BR BRPI1013029A patent/BRPI1013029A2/pt not_active Application Discontinuation
- 2010-05-19 CA CA2968393A patent/CA2968393C/en active Active
- 2010-05-19 DK DK10720803.5T patent/DK2432802T3/en active
- 2010-05-19 LT LTEP16176246.3T patent/LT3112376T/lt unknown
- 2010-05-19 ES ES16176246T patent/ES2721058T3/es active Active
- 2010-05-19 CA CA2762604A patent/CA2762604C/en active Active
- 2010-05-19 SI SI201031697T patent/SI3112377T1/en unknown
- 2010-05-19 ES ES16176249.7T patent/ES2672095T3/es active Active
- 2010-05-19 PL PL10720803T patent/PL2432802T3/pl unknown
- 2010-05-19 SI SI201031358A patent/SI2432802T1/sl unknown
- 2010-05-19 SI SI201031883T patent/SI3112376T1/sl unknown
- 2010-05-19 WO PCT/GB2010/000988 patent/WO2010133828A1/en active Application Filing
- 2010-05-19 DK DK16176249.7T patent/DK3112377T3/en active
- 2010-05-19 TR TR2018/09945T patent/TR201809945T4/tr unknown
- 2010-05-19 EP EP10720803.5A patent/EP2432802B1/en active Active
- 2010-05-19 LT LTEP10720803.5T patent/LT2432802T/lt unknown
- 2010-05-19 AU AU2010250951A patent/AU2010250951B2/en active Active
- 2010-05-19 MX MX2011012184A patent/MX340168B/es active IP Right Grant
- 2010-05-19 JP JP2012511333A patent/JP5667171B2/ja active Active
- 2010-05-19 EP EP16176249.7A patent/EP3112377B1/en not_active Revoked
- 2010-05-19 PT PT16176246T patent/PT3112376T/pt unknown
- 2010-05-19 PL PL16176249T patent/PL3112377T3/pl unknown
- 2010-05-19 CN CN201080022523.6A patent/CN102439034B/zh active Active
- 2010-05-19 HU HUE16176246A patent/HUE043245T2/hu unknown
- 2010-05-19 HU HUE16176249A patent/HUE038342T2/hu unknown
- 2010-05-19 EP EP16176246.3A patent/EP3112376B1/en not_active Revoked
- 2010-05-19 ES ES10720803.5T patent/ES2608653T3/es active Active
- 2010-05-19 HU HUE10720803A patent/HUE032929T2/hu unknown
- 2010-05-19 PL PL16176246T patent/PL3112376T3/pl unknown
-
2014
- 2014-12-11 JP JP2014250885A patent/JP2015096527A/ja active Pending
-
2016
- 2016-12-30 CY CY20161101365T patent/CY1118405T1/el unknown
-
2017
- 2017-01-19 HR HRP20170086TT patent/HRP20170086T1/hr unknown
- 2017-01-23 JP JP2017009529A patent/JP2017110019A/ja active Pending
-
2018
- 2018-05-04 CY CY20181100507T patent/CY1120439T1/el unknown
- 2018-05-15 HR HRP20180757TT patent/HRP20180757T1/hr unknown
- 2018-10-03 US US16/151,144 patent/US20190247512A1/en not_active Abandoned
-
2019
- 2019-04-08 US US16/378,505 patent/US10420846B2/en active Active
- 2019-04-08 US US16/378,501 patent/US10576162B2/en active Active
- 2019-04-08 US US16/378,481 patent/US10517960B2/en active Active
- 2019-04-09 HR HRP20190674TT patent/HRP20190674T1/hr unknown
- 2019-04-12 CY CY20191100410T patent/CY1121558T1/el unknown
- 2019-05-08 JP JP2019088405A patent/JP2019172678A/ja active Pending
-
2022
- 2022-09-02 US US17/929,682 patent/US20230241238A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190674T1 (hr) | Bifunkcionalni polipeptidi | |
RS54424B1 (en) | HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES | |
NZ701040A (en) | Covalently linked antigen-antibody conjugates | |
EP2570137A3 (en) | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) | |
MD3652215T2 (ro) | Moleculă polipeptidică îmbunătăţită cu specificitate duală | |
EP4296673A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
NZ623541A (en) | Human cgrp receptor binding proteins | |
RS52782B (en) | HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR | |
EP2601216A4 (en) | KOVALENTE DIABODIES AND ITS USE | |
SI1883698T1 (sl) | Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato | |
CL2011003148A1 (es) | Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso. | |
WO2017124001A3 (en) | T cell receptor-like antibodies specific for foxp3-derived peptides | |
WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
MX357231B (es) | Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l). | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
EP3970746A3 (en) | Polypeptide variants and uses thereof | |
ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
MX2022006074A (es) | Conjugados y anticuerpos manipulados geneticamente con cisteina. | |
WO2008121615A3 (en) | Antibody formulation | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
TW200732350A (en) | Methods for generating monovalent IgG | |
HRP20240240T1 (hr) | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice | |
NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
MX348166B (es) | Diacuerpos covalentes y sus usos. |